Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

Article Oncology

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

Yuankai Shi et al.

Summary: Rezivertinib showed promising efficacy with a manageable safety profile in patients with EGFR T790M-mutated advanced NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Shun Lu et al.

Summary: This study evaluated the efficacy and safety of Aumolertinib as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer. The results showed that Aumolertinib had significantly longer progression-free survival compared to gefitinib, and the objective response rate and disease control rate were similar between the two drugs. Aumolertinib is a well-tolerated treatment option.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study

Yuankai Shi et al.

Summary: This study evaluated the efficacy and safety of Limertinib in patients with locally advanced or metastatic EGFR T790M-mutated NSCLC. The results showed that Limertinib demonstrated promising efficacy and an acceptable safety profile in these patients.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M thorn NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Shun Lu et al.

Summary: Aumolertinib is an effective and well-tolerated third-generation EGFR TKI for patients with EGFR T790M-positive advanced NSCLC. The study demonstrates high objective response rate and disease control rate, indicating its ability to effectively inhibit tumor progression. It also shows promising results in the treatment of central nervous system metastases. Additionally, Aumolertinib has relatively low side effects, making it a safe and reliable treatment option.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial

Anwen Xiong et al.

Summary: SH-1028, a novel third-generation EGFR tyrosine kinase inhibitor, shows efficacy and tolerability in second-line treatment of advanced NSCLC patients with positive EGFR T790M mutation.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC

Misako Nagasaka et al.

Summary: This review provides an overview of the latest developments in clinical development of third-generation EGFR TKIs, including interim results from some drugs and designs of phase 3 trials, as well as listing other third-generation EGFR TKIs in pipeline development. Additionally, it summarizes the clinical trial results of previously reported third-generation EGFR TKIs and combination clinical trial designs.

JOURNAL OF THORACIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Ying Cheng et al.

Summary: The FLAURA China study evaluated the efficacy of first-line osimertinib in Chinese patients with EGFRm advanced NSCLC, showing significant improvements in PFS and OS compared to comparator EGFR TKIs. Safety data were consistent with the known safety profile of osimertinib.

TARGETED ONCOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre

Yuankai Shi et al.

Summary: Furmonertinib demonstrates promising efficacy and acceptable safety profile in treating patients with EGFR T790M mutated NSCLC, serving as a new treatment option for the Chinese population after first or second generation EGFR TKIs.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Oncology